BidaskClub upgraded shares of Amyris (NASDAQ:AMRS) from a sell rating to a hold rating in a research note released on Monday morning.
Other equities research analysts also recently issued research reports about the stock. HC Wainwright set a $15.00 price objective on shares of Amyris and gave the stock a buy rating in a report on Friday, September 28th. Zacks Investment Research raised shares of Amyris from a strong sell rating to a hold rating in a report on Monday, November 19th. Finally, B. Riley set a $10.00 price objective on shares of Amyris and gave the stock a buy rating in a report on Wednesday, October 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $8.83.
Shares of AMRS opened at $3.94 on Monday. The firm has a market cap of $309.17 million, a PE ratio of -1.29 and a beta of 0.38. Amyris has a 1 year low of $2.92 and a 1 year high of $9.28.
Amyris (NASDAQ:AMRS) last posted its quarterly earnings data on Tuesday, November 13th. The biotechnology company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.96). The company had revenue of $14.90 million for the quarter, compared to analyst estimates of $46.72 million. The firm’s revenue for the quarter was down 38.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.81) earnings per share. Sell-side analysts expect that Amyris will post -1.34 EPS for the current year.
In other Amyris news, CFO Kathleen Valiasek purchased 23,000 shares of the company’s stock in a transaction on Tuesday, November 27th. The shares were purchased at an average cost of $4.37 per share, for a total transaction of $100,510.00. Following the completion of the transaction, the chief financial officer now owns 251,630 shares in the company, valued at $1,099,623.10. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Eduardo Alvarez purchased 11,834 shares of the company’s stock in a transaction on Thursday, December 13th. The stock was acquired at an average price of $4.23 per share, for a total transaction of $50,057.82. Following the completion of the transaction, the chief operating officer now owns 333,876 shares of the company’s stock, valued at approximately $1,412,295.48. The disclosure for this purchase can be found here. 21.80% of the stock is currently owned by insiders.
A number of institutional investors have recently modified their holdings of AMRS. Vivo Capital LLC raised its holdings in Amyris by 97.2% during the 3rd quarter. Vivo Capital LLC now owns 5,575,118 shares of the biotechnology company’s stock worth $44,266,000 after buying an additional 2,748,407 shares during the period. BlackRock Inc. raised its holdings in Amyris by 32.8% during the 3rd quarter. BlackRock Inc. now owns 2,277,432 shares of the biotechnology company’s stock worth $18,082,000 after buying an additional 562,877 shares during the period. Gilder Gagnon Howe & Co. LLC acquired a new stake in Amyris during the 3rd quarter worth about $7,828,000. AWM Investment Company Inc. acquired a new stake in Amyris during the 3rd quarter worth about $5,876,000. Finally, Allianz Asset Management GmbH raised its holdings in Amyris by 56.0% during the 3rd quarter. Allianz Asset Management GmbH now owns 643,630 shares of the biotechnology company’s stock worth $5,110,000 after buying an additional 231,145 shares during the period. Hedge funds and other institutional investors own 32.21% of the company’s stock.
Amyris, Inc, an integrated renewable products company, engages in the research, development, and production of ingredients for the health and wellness, clean beauty, and flavors and fragrances markets worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products.
Read More: Yield Curve
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.